Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
As of today, Regeneron(REGN) shares are valued at $692.58. The company's market cap stands at 72.79B, with a P/E ratio of 16.84 and a dividend yield of 50.1%.
On 2025-12-09, Regeneron(REGN) stock traded between a low of $689.88 and a high of $711.00. Shares are currently priced at $692.58, which is +0.4% above the low and -2.6% below the high.
The Regeneron(REGN)'s current trading volume is 603.61K, compared to an average daily volume of 1.02M.
In the last year, Regeneron(REGN) shares hit a 52-week high of $800.99 and a 52-week low of $476.49.
In the last year, Regeneron(REGN) shares hit a 52-week high of $800.99 and a 52-week low of $476.49.
REGN News
Regeneron (REGN) Pharmaceuticals announced data from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic in adults with newly diagnosed multiple myeloma who wer...
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic (linvoseltamab) in adul...
BMO Capital analyst Evan Seigerman raised the firm’s price target on Regeneron (REGN) to $850 from $725 and keeps an Outperform rating on the shares. Following...
Analyst ratings
67%
of 30 ratingsMore REGN News
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...